Australia’s Therapeutic Goods Administration posted a proposed rework of the agency’s conformity assessment procedures that ...

Sustaining healthy weight loss is about much more than cutting calories or injecting drugs, as many glucagon-like peptide-1 ...

Nia Therapeutics Inc. reported data from an in vivo study of its Smart Neurostimulation System, an AI-based brain-computer ...

Insilico Medicine Cayman Topco has announced a multiyear research and development collaboration with Laboratoires Servier SAS ...

The U.K. National Institute for Health and Care Excellence posted a draft update on its recommendations for ovarian cancer ...

Excessive production of pro-inflammatory cytokines or aging-related chronic inflammation disrupts immunity and diminishes the ...

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive neurodegenerative disorder caused by a CAG ...

Fibrobiologics Inc. has filed an IND application with the FDA seeking to begin first-in-human trials of CYPS-317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of ...

Pacific including deals and partnerships, grants, preclinical data and other news in brief: Adlai Nortye, Arbormed Harbour Biomed, Biogen, Hyloris, Juangsu Aosaikang, Samsung,Takeda Pharmaceutical, ...

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and Vigonvita Shanghai Co. Ltd. have described NMDA and serotonin ...

Hyloris Pharmaceuticals SA has entered into a license agreement with Arbormed Co. Ltd. for exclusive rights in Europe and Turkey to Arbormed’s novel injectable product candidate for Wilson’s disease.